Market Overview

Jim Cramer Weighs In On CarMax, AbbVie And More

Share:
Related KMX
7 Stocks Moving In Tuesday's After-Hours Session
Benzinga's Top Upgrades, Downgrades For July 10, 2018
Related BUD
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
Beer Brands Are Still Losing Fizz: Can Anheuser-Busch Keep From Going Flat?
Beverage sector still reeling from Coca-Cola/cannabis development (Seeking Alpha)

Jim Cramer said on CNBC's "Mad Money Lightning Round" he wouldn't buy CarMax, Inc (NYSE: KMX). He believes the cars have peaked and he wouldn't touch anything in the sector.

Cramer likes Exelon Corporation (NYSE: EXC) very much because he thinks that interest rates are going much higher.

Fiat Chrysler Automobiles NV (NYSE: FCAU) isn't a buy, thinks Cramer. He wants to see who's going to be the new CEO.

Cramer can't recommend Anheuser Busch Inbev NV (ADR) (NYSE: BUD) because the people are less into traditional beers, thinks Cramer.

AbbVie Inc (NYSE: ABBV) should be bought at $92, said Cramer. He likes Abbott Laboratories (NYSE: ABT) more.

Cramer thinks TJX Companies Inc (NYSE: TJX) is going to $115. He's a buyer of the stock.

United Parcel Service, Inc. (NYSE: UPS) is a buy, believes Cramer.

Applied Materials, Inc. (NASDAQ: AMAT) won't be able to hold $39, thinks Cramer. He would rather buy Advanced Micro Devices, Inc. (NASDAQ: AMD).

Cramer wouldn't buy Exelixis, Inc. (NASDAQ: EXEL).

Bank of America Corp (NYSE: BAC) is probably going to $35, said Cramer. He prefers JPMorgan Chase & Co. (NYSE: JPM) and Citigroup Inc (NYSE: C).

Cramer doesn't want to buy Nuance Communications Inc. (NASDAQ: NUAN). He doesn't want to speculate.

Instead of Endo International PLC (NASDAQ: ENDP), Cramer would rather buy Amgen, Inc. (NASDAQ: AMGN).

Posted-In: CNBC Jim Cramer Mad Money mad money Lightning RoundMedia

 

Related Articles (ABT + ABBV)

View Comments and Join the Discussion!

The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

CBS, Constellation Brands, Pfizer, Taiwan Semi: 'Fast Money' Picks For September 7